1st CEE Co-infection – presentations

Local situation in Poland
Dr. M. Parczewski
Local situation in Ukraine
Dr. L. Moroz
Local situation in Romania
Dr. A. Streinu - Cercel
Local situation in Baltic Countries
Dr. S. Caplinskas
Local situation in Czech and Slovak Republics
Dr. V. Aster
Local situation in Turkey
Dr. C. Yurdaydin
Natural History of HCV infection
Dr. K. Simon
Management of End-stage Liver Disease
Dr. M. Puoti
State of the Art treatment of HCV
Dr. S. Bhagani
An integrated approach to HCV treatment in people who inject drugs cross Europe
Dr. M. Maticic
Management of Drug Drug Interactions
Dr. D. Back
Integrase Inhibitirs: Virology and Resistance
Dr. C. Boucher
Clinically relevant Drug Interactions
Dr. S. Khoo
Translation to Clinical Management
Dr. J. Schapiro
Epidemiology of Hepatitis B in Central-Eastern Europe
Dr. A. Streinu - Cercel
State of the Art Treatment of Hepatitis B
Dr. M. Buti
Does hepatitis D in HBV/ HIV co-infected patients affect liver function?
Dr. J. Kozlowska
Antioxidant response in patients with chronic hepatitis B or C.
Dr. K. Wójcik- Cichy
Acute Hepatitis C infection (including cirrhotics)
Dr. C. Boesecke
Chronic Hepatitis C Treatment In Patients Coinfected With HCV/HIV
Dr. S. Fedorchenko
Toll-like receptor 4 polymorphism influence on the clinical course of chronic hepatitis C in HIV-infected patients
Dr. T. Kyrychenko
Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1.
Dr. S. Mauss
Evaluation of early cerebral alterations in the course of HIV and HCV infection using perfusion MR imaging: is the hepatitis C virus more dangerous for the brain?
Dr. J. Bladowska
Impact of HCV coinfection on the development of subclinical atherosclerosis of carotid arteries in HIV positive patients in the Lower Silesia Region, Poland
Dr. K. Barska
Endothelial dysfunction and its influence on the development of subclinical atherosclerosis in HIV/HCV positive patients
Dr. K. Barska